CNR1 and metabolic syndrome: Despite the proven clinical efficacy of the first-generation brain penetrant CB1R antagonist rimonabant in obesity and metabolic syndrome, the clinical use of CB1R antagonists has been abandoned because of psychiatric side effects of rimonabant that are mediated by CB1R in the brain (7).